The Patent Finder

Pearl Therapeutics, Inc.

18 patents currently held · Updated Nov 20, 2026
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

6
Ending by 2030
May 2030
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jun 5, 2027
    The maintenance fee for Drug Delivery Systems and Related Methods (US 11,833,292) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 22, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,324,266Compositions, methods and systems for respiratory delivery of two or more active agents
In force
 · USPTO record
In forceUSPTO record
US 8,703,806Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents
In force
 · USPTO record
In forceUSPTO record
US 9,415,009Compositions, methods and systems for respiratory delivery of two or more active agents
In force
 · USPTO record
In forceUSPTO record
US 9,463,161Compositions for Pulmonary Delivery of Long-Acting Muscarinic Antagonists and Associated Methods and Systems
In force
 · Medium confidence
In forceMedium confidence
US 10,716,753Compositions for Pulmonary Delivery of Long-Acting Muscarinic Antagonists or Long-Acting B2 Adrenergic Receptor Agonists and Associated Methods and Systems
In force
 · Medium confidence
In forceMedium confidence
US 8,808,713Compositions for Pulmonary Delivery of Long-Acting B2 Adrenergic Receptor Agonists and Associated Methods and Systems
In force
 · Medium confidence
In forceMedium confidence
US 8,815,258Compositions, methods and systems for respiratory delivery of two or more active agents
In force
 · USPTO record
In forceUSPTO record
US 11,471,468Methods and systems for conditioning of particulate crystalline materials
In force
 · USPTO record
In forceUSPTO record
US D880,498Display Screen or Portion Thereof With an Animated Graphical User Interface
In force
 · High confidence
In forceHigh confidence
US D899,438Display screen or portion thereof with a graphical user interface
In force
 · High confidence
In forceHigh confidence
10 of 18 patents shown.
Pro members see all 18.
Pro members: see all 18 patents
Also on record, not counted in the 18: 3 patents in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 12 abandoned · 8 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited